CZ303241B6 - Krystalické formy pyrimidinového nukleosidového derivátu - Google Patents

Krystalické formy pyrimidinového nukleosidového derivátu Download PDF

Info

Publication number
CZ303241B6
CZ303241B6 CZ20032111A CZ20032111A CZ303241B6 CZ 303241 B6 CZ303241 B6 CZ 303241B6 CZ 20032111 A CZ20032111 A CZ 20032111A CZ 20032111 A CZ20032111 A CZ 20032111A CZ 303241 B6 CZ303241 B6 CZ 303241B6
Authority
CZ
Czechia
Prior art keywords
crystalline form
compound
crystals
wavelength
rays
Prior art date
Application number
CZ20032111A
Other languages
Czech (cs)
English (en)
Other versions
CZ20032111A3 (cs
Inventor
Takita@Takashi
Ohtsuka@Kelichi
Numagami@Eiji
Harashima@Susumu
Original Assignee
Sankyo Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Company Limited filed Critical Sankyo Company Limited
Publication of CZ20032111A3 publication Critical patent/CZ20032111A3/cs
Publication of CZ303241B6 publication Critical patent/CZ303241B6/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
CZ20032111A 2001-02-09 2002-02-06 Krystalické formy pyrimidinového nukleosidového derivátu CZ303241B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001033128 2001-02-09

Publications (2)

Publication Number Publication Date
CZ20032111A3 CZ20032111A3 (cs) 2003-12-17
CZ303241B6 true CZ303241B6 (cs) 2012-06-13

Family

ID=18896929

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20032111A CZ303241B6 (cs) 2001-02-09 2002-02-06 Krystalické formy pyrimidinového nukleosidového derivátu

Country Status (21)

Country Link
EP (1) EP1364959B1 (cg-RX-API-DMAC7.html)
JP (2) JP3748536B2 (cg-RX-API-DMAC7.html)
KR (1) KR100679904B1 (cg-RX-API-DMAC7.html)
CN (1) CN100408591C (cg-RX-API-DMAC7.html)
AT (1) ATE361929T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002230164B2 (cg-RX-API-DMAC7.html)
BR (2) BRPI0207102A8 (cg-RX-API-DMAC7.html)
CA (1) CA2437994C (cg-RX-API-DMAC7.html)
CY (1) CY1106685T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ303241B6 (cg-RX-API-DMAC7.html)
DE (1) DE60220024T2 (cg-RX-API-DMAC7.html)
DK (1) DK1364959T3 (cg-RX-API-DMAC7.html)
ES (1) ES2286237T3 (cg-RX-API-DMAC7.html)
HU (1) HU229294B1 (cg-RX-API-DMAC7.html)
IL (2) IL157216A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03007123A (cg-RX-API-DMAC7.html)
NZ (1) NZ527393A (cg-RX-API-DMAC7.html)
PT (1) PT1364959E (cg-RX-API-DMAC7.html)
RU (1) RU2256666C2 (cg-RX-API-DMAC7.html)
WO (1) WO2002064609A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200306121B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2081419B1 (en) 1999-09-02 2013-08-07 Ibiden Co., Ltd. Printed circuit board and method of manufacturing printed circuit board
CN101232776B (zh) 1999-09-02 2011-04-20 揖斐电株式会社 印刷布线板
GB0526419D0 (en) 2005-12-23 2006-02-08 Cyclacel Ltd Formulation
GB0625283D0 (en) 2006-12-19 2007-01-24 Cyclacel Ltd Combination
JP5066737B2 (ja) * 2007-04-06 2012-11-07 大鵬薬品工業株式会社 シチジン誘導体を含有する持続静脈内投与用抗腫瘍剤
US8124593B2 (en) 2007-11-05 2012-02-28 Cyclacel Limited Methods of treatment using sapacitabine
GB0808357D0 (en) * 2008-05-08 2008-06-18 Cyclacel Ltd Process
PL2307002T3 (pl) 2008-06-09 2013-05-31 Cyclacel Ltd Kombinacje sapacytabiny lub cndac z inhibitorami metylotransferazy dna, takimi jak decytabina i prokaina
PL2696878T3 (pl) 2011-04-14 2020-01-31 Cyclacel Limited Schemat dawkowania dla sapacytabiny i decytabiny w kombinacji do leczenia ostrej białaczki szpikowej
ES2880109T3 (es) 2012-03-15 2021-11-23 Celgene Car Llc Formas sólidas de un inhibidor de la cinasa del receptor del factor de crecimiento epidérmico
ES2963057T3 (es) * 2015-03-09 2024-03-25 Grace W R & Co Forma cristalina de ribósido de nicotinamida
EP3727400A4 (en) 2017-12-22 2021-10-20 Elysium Health, Inc. CRYSTALLINE FORMS OF NICOTINAMIDE RIBOSIDE CHLORIDE

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0536936A1 (en) * 1991-09-30 1993-04-14 Sankyo Company Limited Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2559917B2 (ja) * 1990-06-15 1996-12-04 三共株式会社 ピリミジンヌクレオシド誘導体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0536936A1 (en) * 1991-09-30 1993-04-14 Sankyo Company Limited Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use
JP2569251B2 (ja) * 1991-09-30 1997-01-08 三共株式会社 ピリミジンヌクレオシド誘導体

Also Published As

Publication number Publication date
HUP0303159A3 (en) 2007-06-28
AU2002230164B2 (en) 2005-04-07
HUP0303159A2 (hu) 2003-12-29
BRPI0207102A8 (pt) 2018-02-27
KR100679904B1 (ko) 2007-02-07
CA2437994C (en) 2011-05-17
WO2002064609A1 (en) 2002-08-22
CZ20032111A3 (cs) 2003-12-17
CN1501939A (zh) 2004-06-02
KR20030081424A (ko) 2003-10-17
IL157216A0 (en) 2004-02-19
ES2286237T3 (es) 2007-12-01
CY1106685T1 (el) 2012-05-23
HU229294B1 (en) 2013-10-28
EP1364959B1 (en) 2007-05-09
ZA200306121B (en) 2005-01-26
CA2437994A1 (en) 2002-08-22
DK1364959T3 (da) 2007-06-04
EP1364959A1 (en) 2003-11-26
NZ527393A (en) 2004-07-30
PT1364959E (pt) 2007-07-23
RU2256666C2 (ru) 2005-07-20
ATE361929T1 (de) 2007-06-15
BR0207102A (pt) 2004-01-27
JP4356998B2 (ja) 2009-11-04
DE60220024T2 (de) 2007-11-22
JP2006008699A (ja) 2006-01-12
EP1364959A4 (en) 2004-03-24
CN100408591C (zh) 2008-08-06
IL157216A (en) 2008-03-20
MXPA03007123A (es) 2003-11-18
JP2002308895A (ja) 2002-10-23
JP3748536B2 (ja) 2006-02-22
RU2003124648A (ru) 2005-02-27
DE60220024D1 (en) 2007-06-21

Similar Documents

Publication Publication Date Title
RU2414470C2 (ru) Кристаллические формы соединения тиазолидиндиона и способ его получения
CN114206878B (zh) 乌帕替尼的晶型及其制备方法和用途
KR100679904B1 (ko) 피리미딘 뉴클레오시드 유도체의 결정
US20040053883A1 (en) Crystalline forms of pyrimidine nucleoside derivative
US8772488B2 (en) Crystals of prasugrel hydrobromate
EP3315493B1 (en) Phenyl amino pyrimidine compound or polymorph of salt thereof
ES3051838T3 (en) Solid state forms of rucaparib salts
KR100909923B1 (ko) N-(2,3-디메틸-5,6,7,8-테트라히드로푸로[2,3-b]퀴놀린-4-일)-2-(2-옥소피롤리딘-1-일)아세트아미드의 다형체
KR20110024057A (ko) 신규한 프라수그렐 황산수소염의 결정다형
KR20260049277A (ko) 5-((3R,55)-3-아미노-5-트리플루오로메틸-피페리딘-1-일)-퀴놀린-8-카르보니트릴HCl 결정형 A1
WO2025032195A1 (en) Crystalline form h1 of 5-((3r,55)-3-amino-5- trifluoromethyl-piperidin-1-yl)-quinoline-8-carbonitrile hemihydrate
WO2020156150A1 (zh) 泊马度胺前体药物盐的多晶型物
CN112334473A (zh) 一种杂芳基并[4,3-c]嘧啶-5-胺类衍生物的晶型及制备方法
JP2007297332A (ja) ベンズアミジン誘導体の結晶

Legal Events

Date Code Title Description
MK4A Patent expired

Effective date: 20220206